candesartan has been researched along with Diabetic Cardiomyopathies in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiac fibrosis is an important causative mechanism of HF associated with diabetes." | 1.42 | CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. ( Byrne, M; Chu, PY; Horlock, D; Jandeleit-Dahm, K; Kaye, DM; Nelson, E; Walder, K; Williams, D; Zimmet, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, PY | 1 |
| Walder, K | 1 |
| Horlock, D | 1 |
| Williams, D | 1 |
| Nelson, E | 1 |
| Byrne, M | 1 |
| Jandeleit-Dahm, K | 1 |
| Zimmet, P | 1 |
| Kaye, DM | 1 |
1 other study available for candesartan and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzylamines; Biphenyl Compounds; | 2015 |